The board of directors of Austar Lifesciences Limited to inform the shareholders of the company and potential investors that, based on the Board's preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2018 and other information currently available, the group is expected to record a decrease in the loss attributable to shareholders of the company for the current period as compared to that for the six months ended 30 June 2017, which was mainly attributable to the following factors: an increase in revenue mainly resulting from the increased in closing value of backlog as at 31 December 2017 as compared with that of 31 December 2016, which part of amount were recognized as revenue in the Current Period; an increase in gross profit mainly attributable to the improved project execution management and cost control measures for the business segment of Liquid and Bioprocess System which is the major revenue contributor of the Group for the Current Period as compared with the corresponding period in 2017; and an increase in revenue and gross profit from the business segment of Life Science Consumables. Nonetheless, the effect of such increase is partially offset by the increase in administrative expenses, selling and marketing expenses and research and development expenses.